Ed is a research scientist at Pangea Bio and works on R&D projects across our early stage pipeline.
Prior to joining Pangea Bio, Ed spent six years as a Biochemist at KalVista Pharmaceuticals, a company focused on developing small molecule protease inhibitors for the treatment of rare diseases. In this role, he led biochemical profiling of compounds and supported their progression from benchtop into the clinic. Ed was lead author on a paper describing the pharmacology of Sebetralstat, a compound used for the acute treatment of Hereditary Angioedema.
Ed holds a BSC in Biochemistry from the University of Bristol, the city he has made his home.